Background-Macrophage migration inhibitory factor (MIF) is a structurally unique inflammatory cytokine that controls cellular signaling in human physiology and disease through extra-and intracellular processes. Macrophage migration inhibitory factor has been shown to mediate both disease-exacerbating and beneficial effects, but the underlying mechanism(s) controlling these diverse functions are poorly understood. Methods and Results-Here, we have identified an S-nitros(yl)ation modification of MIF that regulates the protective functional phenotype of MIF in myocardial reperfusion injury. Macrophage migration inhibitory factor contains 3 cysteine (Cys) residues; using recombinant wtMIF and site-specific MIF mutants, we have identified that Cys-81 is modified by S-nitros(yl)ation whereas the CXXC-derived Cys residues of MIF remained unaffected. The selective S-nitrosothiol formation at Cys-81 led to a doubling of the oxidoreductase activity of MIF. Importantly, S-nitrosothiol-MIF formation was measured both in vitro and in vivo and led to a decrease in cardiomyocyte apoptosis in the reperfused heart. This decrease was paralleled by a S-nitrosothiol-MIF-but not Cys81 serine (Ser)-MIF mutant-dependent reduction of infarct size in an in vivo model of myocardial ischemia/reperfusion injury. Conclusions-S-nitros(yl)ation of MIF is a pivotal novel regulatory mechanism, providing enhanced activity resulting in increased cytoprotection in myocardial reperfusion injury. (Circulation. 2012;125:1880-1889.) 
M yocardial inhibitory factor (MIF) is a structurally unique inflammatory cytokine that plays an important role as an upstream regulator of innate and acquired immunity as well as in cellular redox signaling. Because of its inflammatory activities, MIF is a mediator of a number of acute and chronic inflammatory diseases. [1] [2] [3] [4] [5] [6] This includes an exacerbating role in atherosclerosis, a major underlying cause of cardiovascular disease in the Western world. [7] [8] [9] [10] However, accumulating evidence indicates that the role of MIF in cardiovascular pathology is more complex. MIF regulates key functions in myocardial ischemia/reperfusion (I/R) injury with an overall cardioprotective activity profile. [11] [12] [13] [14] Mechanistically, this property involves protection against c-Jun N-terminal kinase (JNK)-mediated apoptosis and against oxidative cell stress which prominently occurs during the early phase of reperfusion in myocardial infarction. Protection conferred by MIF against redox stress has been attributed to its intrinsic thiol-protein oxidoreductase (TPOR) activity. 1, 5, 11, 15 Clinical Perspective on p 1889 MIF's role in redox regulation is due to its structural properties which are unique within the protein family of cytokines and plays a critical role in cellular redox homeostasis and apoptosis inhibition. 1, 11, 15 The TPOR activity of MIF is mediated through a conserved Cys 57 -Ala-Leu-Cys 60 motif 15 resembling the CXXC motif of TPORs like thioredoxin (TRX). Moreover, residue Cys-60 is crucial for the interaction interface between MIF and c-Jun N-terminal activation domain binding protein-1 (JAB1/CSN5), an interaction partner of intracellular MIF. 16 MIF engages in several defined protein-protein interactions with both extra-and intracellular binding partners. The third cysteine in MIF, Cys-81, has been suggested to mediate conformational effects. 17 However, posttranslational modifications that could serve to control the action and magnitude of such interactions have been unknown.
Protein S-nitros(yl)ation constitutes a large part of the nitric oxide (NO • )-mediated effects throughout physiology as well as in a broad spectrum of human diseases. 18 S-nitros(yl)ation is the coupling of an NO • moiety to a reactive Cys thiol to form an SNO. That could occur by endogenous NO • -generating agents such as N 2 O 3 , by transition metal-catalyzed addition of NO • or by transnitros(yl)ation from low-molecular-weight SNOs, such as S-nitroso-Cys. 19 Furthermore, • NO 2 possibly mediates an one-electron oxidation of thiols with subsequent reaction of thiyl radicals with NO • . This protein modification has emerged as an important mechanism for dynamic, posttranslational regulation of most or all main classes of proteins. 19 S-nitros(yl)ation of selective Cys thiol groups can modulate the action of specific target proteins and thus regulates their function and properties. 19 -21 There is accumulating evidence that S-nitros(yl)ation of proteins is intimately linked with myocardial I/R injury mediating cardioprotection. 22 A number of studies demonstrated that NO • is generated from both NO synthases (NOS)-dependent and NOS-independent pathways. [23] [24] [25] [26] [27] During I/R, nitrite reduction to NO • is an important source of NO • that can be used for S-nitros(yl)ation. 28 In this study, we set out to test whether S-nitros(yl)ation of MIF may regulate the protective functional phenotype of MIF in myocardial reperfusion injury. We reasoned that if MIF is posttranslationally modified by S-nitros(yl)ation, S-nitros(yl)ated MIF could play a fundamental role in myocardial I/R injury.
Methods

Recombinant Wild-Type Human MIF and Site-Specific Mutants of MIF
Recombinant wild-type human MIF (wtMIF) and the Cys mutants Cys57Ser-MIF, Cys60Ser-MIF, and Cys81Ser-MIF used in this study were expressed, purified, and folded as described previously. 29
Reductive Gas-Phase Chemiluminescence
The amount of S-nitrosothiol (SNO)-MIF formation after S-nitros(yl)ation of wtMIF or the Cys-Ser substitution mutants was determined by reductive cleavage of the SNO bond with an iodide/triiodidecontaining reaction mixture and subsequent determination of the NO • released into the gas phase by its chemiluminescence reaction with ozone within a chemiluminescence detector as described previously. 30, 31 
Synthesis of S-Nitros(yl)ated MIF
S-nitros(yl)ation of wtMIF was achieved by reduction of nitrite to NO • from deoxygenated myoglobin (deoxyMb). 29, 30 This approach prevents false-positive chemiluminescence signals from conventionally applied NO • donors in the incubation solution (eg, via S-nitroso-Cys). In brief, horse heart Mb was dissolved in PBS to a final concentration of 200 mol/L. After deoxygenation by gassing with argon for 15 to 20 minutes, deoxyMb was quantified spectrophotometrically (ϭ542 nm; 542 ϭ13.9 cm Ϫ1 mM Ϫ1 ). A 5 mmol/L nitrite solution was anoxically prepared and added at a final concentration of 25 mol/L to the deoxyMb solution. NO • formation was confirmed by chemiluminescence. Incubation of 400 nmol/L wtMIF with 25 mol/L nitrite and 200 mol/L deoxyMb was carried out in the dark for 1 hour at 37°C. To specify the distinct S-nitros(yl)ation site within MIF, the Cys-Ser replacement mutants Cys57Ser-, Cys60Ser-or Cys81Ser-MIF were used instead of wtMIF. After 1 hour, SNO measurement was performed via chemiluminescence. Alkylation of Cys residues via preincubation of wtMIF with 100 mmol/L N-ethylmaleimide (NEM) before S-nitros(yl)ation or omitting deoxyMb in the incubation tube served as negative controls.
Hydroxyephedrine Transhydrogenase Assay
Catalytic redox activity of wtMIF and SNO-MIF was measured by the 2-hydroxyethyldisulfide (HED) transhydrogenase assay which was performed as described previously. 32 Briefly, reduction of HED by reduced glutathione was measured in a MIF-catalyzed reaction. Oxidation of NADPϩ by oxidized glutathione was then recorded photometrically in a coupled step (ϭ340 nm). For each measurement, 25 g wtMIF dissolved in 20 mmol/L sodium phosphate buffer (pH 7.2) was used. S-nitrosothiol-MIF formation was achieved by incubating wtMIF with 250 mol/L S-nitroso-Cys for 30 minutes at 37°C in the dark as described previously. 33 The transhydrogenase reaction was started by adding wtMIF or SNO-MIF to 450 L of the reaction mixture (final volume: 600 L; final MIF concentration: 3.4 mol/L). Equal volumes of 20 mmol/L sodium phosphate buffer and sodium phosphate buffer with 250 mol/L S-nitroso-Cys (pH 7.2) served as controls. Reactions were recorded for 12 minutes, and MIF activity was calculated from the linearized slope of the curve (⌬ 340 nm). Values represent the meanϮSD of 3 independent assays with at least duplicate incubations each.
Detection of S-Nitros(yl)ated Proteins by Biotinylation (Biotin-Switch Assay) and Western Blotting
The biotin-switch assay was essentially performed as described previously with minor modifications. 34 Homogenization and blocking step: Excised and perfused mouse hearts were weighed and homogenized immediately in 20 volumes of ice-cold HEN buffer (250 mmol/L Hepes, 10 mmol/L EDTA, 2 mmol/L NEM, 0.1 mmol/L neocuproine) to block free thiols, by using a Wheaton glass-glass homogenizer immersed in an ice/water bath. The homogenate was centrifuged at 70 000 g for 1 hour at 4°C. The supernatant was incubated for 30 minutes at room temperature in the dark. Biotinylation step: The supernatant was precipitated twice with 5 volumes of ice-cold acetone to remove unreacted NEM, and the pellet was resuspended in HENS buffer (Hepes 250 mmol/L, EDTA 1 mmol/L, neocuproine 0.1 mmol/L, and 1% SDS). Subsequently, proteins were incubated with 1/3 volume of 4 mmol/L N-(6-(biotinamido)hexyl)-3Ј-(2Ј-pyridyldithio)propionamide (biotin-HPDP, Pierce). Ascorbate and copper (1 mmol ⅐ L Ϫ1 ⅐ 10 nmol/L Ϫ1 ) were added to reduce SNO bonds and the mixture was incubated for 1 hour at room temperature in the dark. After another ice-cold acetone precipitation to remove unreacted biotin-HPDP, the pellet was resuspended in HENS buffer. Western blot analysis: For the specific detection of S-nitros(yl)ated MIF, proteins were immobilized after the biotinylation step via neutravidin resin-coated spin columns and subsequently pulled down according to the manufacturer instructions (Pierce, Pull-Down Biotinylated Protein: Protein Interaction Kit). After pull-down, affinity-purified biotinylated proteins from heart homogenates and MIF were revealed by Western blotting using the MIF-specific antibody Ka565 (1:1000) as described. 35 Macrophage migration inhibitory factor bands were quantified using Quantity One 1-D analysis software and normalized to the signal of a recombinant MIF band. Amber tubes were used in all these procedures, and the reactions were carried out in the dark to avoid unspecific photolysis of SNO bonds from light.
Myocardial I/R Injury In Vivo Protocol
Wild-type (WT) and MIF-deficient (Mif Ϫ/Ϫ ) mice were anesthetized by i.p. injection of ketamine (100 mg/kg) and xylazin (10 mg/kg) and intubated. Mechanical ventilation parameters were set to a tidal volume of 2.1 to 2.5 mL and a respiratory rate of 140 breaths per min. Deep anesthesia was maintained by adding 2 vol% isoflurane to the ventilation gas. The chest was opened through a midline sternotomy, and the left coronary artery (LCA) was ligated for 30 minutes. S-nitrosothiol formation was induced by injection of 1.67 mol/kg nitrite (in 50 L 0.9% sodium chloride) into the left ventricular cavity 5 minutes before reperfusion. 28 Sodium chloride injection (50 L) served as control treatment. The wtMIF (10 g) and the Cys81Ser-MIF mutant (10 g), respectively, were injected into the Mif Ϫ/Ϫ mice 5 minutes before onset of ischemia. For detection of SNO-MIF and investigation of apoptosis respectively, hearts were excised after 5 minutes or 4 hours of reperfusion and treated as described in the Methods section of the online-only Data Supplement. For analysis of infarct size, mice were euthanized after 24 hours of reperfusion; hearts were excised and perfused with PBS (for TTC staining see Methods section of the online-only Data Supplement).
Supplemental Methodology
For a detailed explanation of experimental animals and the methods relative to organ harvest for SNO analysis, myocardial area at risk and infarct size measurements, determination of myocardial apoptosis, coimmunoprecipitation of JAB1/CSN5 and Cys81Ser-MIF, identification of S-nitros(yl)ation sites by mass spectrometry, please see the Methods section of the online-only Data Supplement.
Statistical Analysis
The results are presented as meanϮSD unless stated otherwise. Data were analyzed by 1-way ANOVA and posthoc Bonferroni multiple comparison correction (for all pairwise tests) with GraphPad Prism 5 software to compare differences between multiple groups and Student unpaired t test when analyzing 2 groups. Testing of main effects and 2 specific interactions was performed using 2-way ANOVA with posthoc Dunn-Š idák multiple comparison. A P value Ͻ0.05 was considered statistically significant.
Results
MIF Is Selectively S-Nitros(yl)ated at Cys-81
Cysteine residues are highly reactive groups and more recently have been identified to be targeted by posttranslational modifications such as S-nitros(yl)ation, serving critical regulatory purposes in cellular signaling and redox homeostasis. We investigated whether the MIF Cys residues are accessible to S-nitros(yl)ation. Reduction of nitrite to NO • was employed to synthesize SNO-MIF. Nitrite reduction was achieved by the nitrite reductase activity of deoxyMb. 27 S-nitrosothiol formation was measured by gas-phase chemiluminescence. 31 Macrophage migration inhibitory factor was reproducibly and robustly modified by NO • , and quantification showed a ratio of 1.4Ϯ0.4 nmol SNO/nmol wtMIF, indicating that likely only 1 of the 3 Cys residues in MIF was modified ( Figure  1A) . To confirm the specificity of the detected SNO signal, the thiol groups of the MIF Cys were alkylated with NEM before S-nitros(yl)ation. This resulted in a complete ablation of MIF S-nitros(yl)ation ( Figure 1A) . Similarly, omission of nitrite reduction in the reaction also prevented the formation of SNO-MIF. These data provided clear evidence that MIF can be S-nitros(yl)ated in vitro. To identify the specific Cys residue(s) that is/are S-nitros(yl)ated in MIF, SNO-MIF synthesis was performed using the site-specific MIF mutants Cys57Ser-MIF, Cys60Ser-MIF, and Cys81Ser-MIF in which 1 of the 3 Cys residues is isosterically substituted by a Ser residue ( Figure 1B ). 15 Strikingly, SNO-MIF formation was completely abolished in Cys81Ser-MIF whereas the Cys57Ser and Cys60Ser mutants showed S-nitros(yl)ation ratios that were comparable to that of wtMIF (1.3Ϯ0.6 and 0.9Ϯ0.4 nmol SNO/nmol MIF) ( Figure 1C ). These findings clearly demonstrated that MIF is a target for S-nitros(yl)ation in vitro and that this modification selectively targets Cys-81. Figure 1D illustrates the position of Cys-81 in the structure of the MIF monomer and trimer and indicates where the nonmodifiable Cys-57 and Cys-60 are located.
Myocardial SNO-MIF Formation In Vivo
After having demonstrated that MIF can be modified by S-nitros(yl)ation in vitro, we next investigated whether SNO-MIF formation can be detected in I/R in vivo. We used the biotin-switch technique 34 to evaluate whether SNO-MIF formation occurs in the reperfused mouse heart under in vivo conditions. Wild-type mice underwent occlusion of the LCA for 30 minutes, and either saline or nitrite was administered 5 minutes preceding reperfusion (Figure 2A ). After 5 minutes of reperfusion, hearts were excised, homogenized, and subjected either to gas-phase chemiluminescence for the detection of total SNO content ( Figure 2B ) or to the biotin-switch assay for specific detection of SNO-MIF in myocardial tissue. This experiment revealed that nitrite treatment led to a dramatic increase of total SNO content as well as specific formation of SNO-MIF in the postischemic heart in vivo ( Figure 2C ). Quantitative analysis showed that SNO-MIF levels increased Ϸ10-fold after myocardial I/R when compared with the basal level ( Figure 2D ). Pharmacological inhibition of NOS-mediated NO • generation before I/R did not affect basal SNO-MIF level (online-only Data Supplement Figure I) , indicating that the SNO-MIF levels as observed in the experiment were not primarily dependent on NOS-generated NO • . Thus, we have demonstrated for the first time that SNO-MIF formation occurs in the heart in vivo and that SNO-MIF levels become markedly elevated by increased concentrations of S-nitros(yl)ation-active groups during myocardial I/R.
S-Nitros(yl)ation of MIF Is Site Specific In Vivo
S-nitrosothiol formation at Cys thiols depends on precise biochemical conditions that an NO • group could encounter, such as O 2 concentration, hydrophobicity, nucleophilicity, and the redox environment surrounding the target thiol, conditions that could dramatically change during I/R in the myocardium. Besides these ambient conditions, protein characteristics themselves, such as the ultrastructural accessibility of a given Cys residue, can change during I/R and might determine whether a particular thiol in a given protein is subjected to S-nitros(yl)ation or not. 36 On the basis of this background, we examined whether the specific S-nitros(yl)ation of Cys-81 in the MIF sequence that we had observed in vitro could also be detected in the myocardium in vivo during I/R. To determine the site of MIF S-nitros(yl)ation in vivo, we used an LC-MS/MS approach. 37 Before the biotin-switch assay and subsequent MS analysis were performed, mice underwent transient LCA occlusion followed by a reperfusion (Figure 2A ). After trypsinolysis of the biotinylated proteins, MS sequencing revealed that the MIF peptide LLC 81 GLLSDR was biotinylated at Cys-81 whereas no other biotinylated MIF peptide fragments were detected (Figure 3 ). Because no unmodified Cys-81 peptide was identified, an efficiency of S-nitros(yl)ation of almost 100% after nitrite treatment can be assumed. However, if the unmodified MIF peptide LLC 81 GLLSDR reacted differently to the LC material this might lead to nonidentification of this particular fraction. This finding confirmed our in vitro observations and unambiguously demonstrated that MIF is selectively S-nitros(yl)ated at Cys-81 in the reperfused heart in vivo. In fact, this is the first demonstration of a posttranslational modification in vivo of the MIF protein, which moreover appears to be linked to critical physiological and pathophysiological conditions.
S-Nitros(yl)ation of MIF Modulates MIF Activities In Vitro and in Myocardial I/R Injury In Vivo
Within the TPOR family of redox-regulatory proteins, S-nitros(yl)ation of the noncatalytic Cys residues can critically contribute to an alteration of the functions of these proteins, including their CXXC-dependent oxidoreductase activity. 21 The TPOR activity of MIF reduces smallmolecular-weight disulfides such as HED, and this activity is dependent on the presence of Cys-60 and in part on Cys-57. 15 Applying the HED transhydrogenase assay 15, 17 and comparing the HED activity of wtMIF with that of SNO-MIF, we next asked whether the observed SNO modification would affect the catalytic TPOR activity of MIF. S-nitrosothiol-MIF was synthesized by preincubation of wtMIF with S-nitroso-Cys . 33 S-nitroso-Cys led to an S-nitros(yl)ation of Cys-81 of 88Ϯ19% (nϭ3) (online-only Data Supplement Figure II) and had no influence on assay kinetics (online-only Data Supplement Figure III) . S-nitrosothiol -MIF catalyzed the formation of HED at a markedly faster rate ( Figure 4A ) being twice (205Ϯ15%) as active as wtMIF (100%) ( Figure 4B ). This faster rate indicated that modification of Cys-81 resulted in a conformational change that promoted the redox activity of MIF. Interestingly, this observation was in line with prior findings showing that alkylation of Cys-81 promoted the redox activity of MIF. 15 Taken together, these results demonstrate that S-nitros(yl)ation of MIF at Cys-81 increases the inherent catalytic oxidoreductase activity of this protein.
Because activity as well as protein-protein interactions of the active site of MIF has been linked to reduction of apoptosis, 1, 16 we next asked whether S-nitros(yl)ation also causally affects the activities of MIF in vivo. We were particularly interested in the effect that MIF S-nitros(yl)ation may have on 
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the cardioprotective properties of MIF during myocardial I/R. Protection of cardiomyocytes from apoptosis has been identified as an important mechanism related to the cardioprotective activity of MIF. We compared mouse heart apoptotic cell numbers between WT mice and mice genetically deficient in MIF after I/R and treatment with nitrite. Hearts were harvested 4 hours after the reperfusion interval was started. After subsequent immunohistochemical preparation of the excised hearts, cardiomyocyte apoptosis was determined and quantified by TUNEL staining. Visual inspection of the TUNEL stains ( Figure 4C ) already indicated that the lowest number of TUNEL-positive cells was seen in hearts from WT mice treated with nitrite, whereas the highest number of TUNELpositive cells was observed in Mif Ϫ/Ϫ cells that did not receive nitrite. Quantification of the TUNEL analysis in relation to the area at risk confirmed this notion and showed that SNO formation in WT mice led to a markedly decreased number of apoptotic nuclei (2.1Ϯ1.0%) compared with control treatment of these mice (8.0Ϯ3.5%; Figure 4D ). These observations were in line with prior findings from others. 38 Ischemia/reperfusion in Mif Ϫ/Ϫ mice that did not receive nitrite treatment resulted in a markedly increased myocardial apoptosis rate compared with the control-treated WT mice (14.5Ϯ1.0% versus 8.0Ϯ3.5%, PϽ0.05; Figure 4D ), confirming that MIF exhibits antiapoptotic functions in the reperfused heart. Intriguingly, SNO-mediated inhibition of apoptosis after I/R was attenuated in Mif Ϫ/Ϫ mice (11.3Ϯ4.3%; Figure 4D ). Of note, the relative reduction in apoptosis after SNO formation was 75% in WT mice (8.0Ϯ3.5% versus 2.1Ϯ1.0%) whereas the attenuation of apoptotic nuclei was only 22% in Mif Ϫ/Ϫ mice (14.5Ϯ1.0% versus 11.3Ϯ4.3%; Figure 4D ). It has previously been suggested that the antiapoptotic effect of MIF in the reperfused heart is mediated through an inhibition of the JNK pathway. 14 We had observed that S-nitros(yl)ation of MIF at Cys-81 led to an alteration of the Cys-60 -dependent TPOR activity of MIF. Because Cys-60 is critically involved in the interface between MIF and JAB1 and because MIF/JAB1 interaction blocks JNK activity, 16 we investigated whether MIF/JAB1 binding activity could be affected by Cys-81. Coimmunoprecipitation analysis revealed that the Cys81Ser substitution markedly decreased the binding between MIF and JAB1 (100% versus 31Ϯ25%; PϽ0.001) (online-only Data Supplement Figure  IV) . Importantly, modification of Cys-81 by S-nitros(yl)ation in vivo also led to a marked decrease in the interaction between MIF and JAB1 as revealed by coimmunoprecipitation after LCA occlusion/reperfusion and nitrite-mediated SNO formation in vivo. These in vitro and in vivo results suggest that S-nitros(yl)ation increases the cellular availability of MIF in the early phase of reperfusion by decreased JAB1 trapping 39 and thus mediates increased cardioprotection (online-only Data Supplement Figure V ).
S-Nitros(yl)ation at Cys-81 Regulates the Cardioprotective Properties of MIF In Vivo
We have demonstrated that MIF is selectively S-nitros(yl)ated at Cys-81 and that this posttranslational modification regulates the antiapoptotic activity of MIF during I/R. To elucidate whether the selective SNO modification of MIF is central to MIF-mediated cardioprotection in myocardial I/R, we compared infarct size in Mif Ϫ/Ϫ mice after myocardial I/R on wtMIF application and SNO generation ( Figure 5A ). Injection of wtMIF into the left ventricular cavity of Mif Ϫ/Ϫ hearts reduced infarct size (35Ϯ5% versus 30Ϯ2%, PϽ0.05; Figure  5B ) to the level of WT mice, which naturally show smaller infarct size compared with Mif Ϫ/Ϫ (online-only Data Supplement Figure VI) . Application of wtMIF undergoing SNO formation further reduced infarct size to 8Ϯ2% in Mif Ϫ/Ϫ mice. Infarct size reduction in Mif Ϫ/Ϫ hearts undergoing SNO formation without wtMIF reconstitution was less pronounced (17Ϯ3%; Figure 5B ). Because SNO-MIF formation was found to selectively represent S-nitros(yl)ation at Cys-81, we applied the Cys81Ser-MIF mutant control instead of wtMIF. Determination of the resulting infarct sizes revealed that SNO-mediated cardioprotection was significantly less pro-nounced when Cys81Ser-MIF was injected instead of wtMIF (16Ϯ4% versus 8Ϯ2%, PϽ0.05; Figure 5B ). Injection of the Cys81Ser-MIF mutant without nitrite led to an infarct size of 33Ϯ3% ( Figure 5B ). In summary, these results demonstrate that MIF is selectively S-nitros(yl)ated at Cys-81 and that this previously unrecognized posttranslational modification regulates MIF function and increases the cardioprotective properties of MIF in vivo.
Discussion
During the early phase of myocardial reperfusion, S-nitros(yl)ation modulates the activity of various proteins involved in apoptosis and oxidative stress. 22 Myocardial MIF functions as an endogenous protection mechanism against lethal I/R injury. It appears that cardioprotection by MIF is especially relevant within the first minutes of reperfusion. 11, 12, 14 However, whether this critical cardioprotective activity of MIF may be modulated or switched on by posttranslational modifications has not been addressed. Here, we have identified S-nitros(yl)ation as the first-described posttranslational modification of MIF and provide evidence that S-nitros(yl)ation of MIF is critical for its cytoprotective properties in the reperfused myocardium in vivo.
Protein Cys residues are intrinsically nucleophilic and reactive under physiological pH conditions. Their reactivity renders them amenable to engage in diverse biochemical functions such as disulfide formation, protein-protein interaction, redox catalysis, or redox signaling. 40 The MIF sequence contains 3 Cys residues, which have been found to contribute to several of the functional properties of MIF. Cysteine-57 and Cys-60 form a CXXC motif that has catalytic TPOR activity in vitro and is a distinct hallmark of the TPOR protein family. Best characterized is the role of Cys-60, which has been shown to contribute to MIF functions such as inhibition of apoptosis, JAB1, and NM23-H1 bind- ing. 1, 16, 41, 42 The role of the third, non-CXXC Cys residue in MIF, Cys-81, has hardly been studied, with Cys-81 being thought to contribute to the interaction between MIF and p53. 43 However, Cys-81 is critically situated in an ␣-helix of the MIF structure where it contributes to the hydrophilic surface area. 17 Yet Cys-81 is mostly surrounded by hydrophobic amino acids. Consequently, substitution or modification of Cys-81 may alter hydrophobic interactions in this region, and substitution of Cys-81 has been thought to mediate conformational effects. 17 Macrophage migration inhibitory factor binding of JAB1 inhibits JNK activation and subsequent c-Jun phosphorylation. Furthermore, MIF blocks JNK activation and cellular apoptosis elicited by thiol starvation. 1 Importantly, Qi et al demonstrated that MIF-mediated inhibition of the JNK pathway during myocardial reperfusion decreased cardiomyocyte apoptosis in the reperfused myocardium, representing a major axis of the cardioprotective MIF pathway. 14 Our present findings demonstrate that, although Cys-60 of MIF is part of the binding interface between MIF and JAB1, the MIF/JAB1 interaction critically depends on Cys-81, because deletion of this amino acid significantly attenuated JAB1 binding. An involvement of Cys-81 in the protein-protein interaction between MIF and JAB1 was surprising at first sight because this residue is remotely situated from the binding interface encompassing residues 50 to 65. However, modification of distant regulatory Cys residues by S-nitros(yl)ation has previously been shown to be essential. For example, S-nitros(yl)ation of nonactive site Cys is known to regulate the function of proteins like TRX or G-protein-coupled receptor kinase 2, 21, 44 and currently numerous potentially functional Cys residues in the mammalian proteome have remained unidentified. 40 In fact, MIF can be S-nitros(yl)ated, as demonstrated herein, and Cys-81 clearly turned out to be the only target site Activity is expressed as a decrease of absorbance over time. S-nitrosothiol-MIF catalyzed reduction of HED in the HEDtranshydrogenase assay (2.48Ϯ0.52 nkat) was markedly increased compared with wtMIF (1.28Ϯ0.28 nkat) (meanϮSEM; nϭ3, **PϽ0.02). B, Repetitive experiments revealed that S-nitros(yl)ation significantly increased the activity of SNO-MIF (205Ϯ15%) compared with wtMIF (meanϮSD; nϭ3, **PϽ0.02). C, TUNEL staining of heart sections from WT and Mif Ϫ/Ϫ mice after 30 minutes myocardial ischemia and 4 hours reperfusion in vivo. Exemplary pictures show increased apoptotic cells in Mif Ϫ/Ϫ compared with WT. S-nitrosothiol formation in WT hearts decreased apoptosis markedly but was less pronounced in SNO-MIF-deficient hearts. D, Quantitative analysis of TUNEL-stained heart sections, displayed as apoptotic cells per area at risk. Bars show significantly decreased apoptosis level after SNO formation in WT mice (black bars). Lack of SNO-MIF markedly attenuates SNO-mediated cardioprotection in Mif Ϫ/Ϫ mice (gray bars) (meanϮSD; nϭ4, *PϽ0.05). wtMIF indicates wild-type macrophage migration inhibitory factor; SNO, S-nitrosothiol; CTRL, control; AAR, area at risk; nkat, nanokatal; and NS, not significant.
for this posttranslational modification. Thus, it was of high interest whether this residue might be a novel regulatory locus that on modification may affect MIF's functions under redox stress.
As discussed above, MIF is a regulator of the cellular redox state and potently inhibits apoptosis during myocardial I/R. 11, 12, 14 Interestingly, Koga et al, in a mouse model in vivo, established a direct link between MIF-mediated reactive oxygen species quenching and protection of the heart from I/R injury. 11 This effect was attributed to the TPOR activity of the CXXC motif of MIF. We investigated whether the TPOR activity of MIF would be affected by the Cys-81-dependent S-nitros(yl)ation of MIF. Notably, reduction of the small molecule disulfide HED by MIF was significantly enhanced after S-nitros(yl)ation.
It was of great interest to ask whether the SNO formation at Cys-81 observed in vitro was also detectable under in vivo conditions during myocardial I/R. Nitrite reduction is an important source of NO • during I/R that enables S-nitros(yl)ation and thus attenuates I/R injury. 28, 45, 46 Accordingly, SNO levels increased after nitrite application during I/R in our in vivo model. Importantly, we were able to detect SNO-MIF in the reperfused heart applying the biotin-switch technique and demonstrated the specificity of SNO formation at Cys-81 by LC-MS/MS analysis.
S-nitros(yl)ation has been shown to regulate the function of several cardioprotective proteins such as TRX, Gprotein-coupled receptor kinase 2, or caspase 3. 20, 46, 47 Here we have identified MIF as an important novel target for S-nitros(yl)ation during I/R in vivo. Macrophage migration inhibitory factor is a protein mediator that both acts as an inflammatory cytokine/chemokine and exhibits cardioprotective effects because of its intracrine/paracrine activity. This effects of MIF raised the question whether the posttransla-tional S-nitros(yl)ation of MIF affected its cardioprotective properties. We found significantly increased rates of cardiomyocyte apoptosis in mice that lacked SNO-MIF and that had been subjected to I/R in vivo. Because these results were based on the genetic deletion of MIF, we investigated whether replenishment of SNO-MIF in the Mif Ϫ/Ϫ mice was able to reverse the observed phenotype. In fact, administration of wtMIF, which also led to a reinstallation of SNO-MIF levels, led to a marked reduction in infarct sizes in these mice, confirming the importance of MIF and demonstrating the impact of SNO-MIF in reperfusion injury of the myocardium. Thus, these data extended previous findings of Young et al who could show that application of wtMIF into Mif Ϫ/Ϫ hearts reconstitutes WT conditions ex vivo. 14 Of note, the Cys81Ser-MIF mutant failed to reinstall the cardioprotective properties of MIF in Mif Ϫ/Ϫ mouse hearts, underscoring the role of SNO-MIF and the specific function of S-nitros(yl)ation at Cys-81 in cardioprotection.
In summary, we have identified a novel posttranslational modification of the MIF protein. We could demonstrate that key functions of MIF are regulated by its S-nitros(yl)ation, with fundamental effects on myocardial I/R injury in vivo. S-nitros(yl)ation thus might provide a new therapeutic strategy for regulating the functions of MIF during the early phase of reperfusion.
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This study was supported by the Deutsche Forschungsgemeinschaft (DFG) grants Be1977/4-2 (TP1 of DFG-FOR809) and GRK1508/1 (project P13) and by the IZKF Aachen grant K1-4 to Dr Bernhagen, Figure 5 . S-Nitros(yl)ation at Cys-81 increases cardioprotective properties of MIF after myocardial I/R injury in vivo. A, Experimental protocol. Mif Ϫ/Ϫ mice underwent transient regional ischemia followed by reperfusion and subsequent analysis of infarct size per area at risk. Recombinant mouse MIF (wtMIF) or the non-S-nitros(yl)able Cys81Ser-MIF mutant was applied in Mif Ϫ/Ϫ mice. Nitrite was applied to mediate S-nitros(yl)ation. B, Reconstitution of wtMIF in Mif Ϫ/Ϫ mice decreased infarct size (35Ϯ5% to 30Ϯ2%; *PϽ0.05). Nitrite reduced infarct size to 17Ϯ3%. Reconstitution of wtMIF after SNO formation by nitrite reduced infarct size in Mif Ϫ/Ϫ mice to 8Ϯ2%. This cytoprotective effect was less pronounced on application of the non-S-nitros(yl)able Cys81Ser-MIF mutant in conjunction with nitrite (35Ϯ5% to 16Ϯ4%) or the Cys81Ser-MIF mutant solely (35Ϯ5% to 33Ϯ3%). The cytoprotective effect mediated by SNO-MIF compared with the non-S-nitros(yl)able Cys81Ser-MIF is displayed black shaded (*PϽ0.05) (meanϮSD; nϭ5-9, *PϽ0.05, ***PϽ0.001). I/R indicates ischemia/reperfusion; LCA, left coronary artery; CTRL, control; rMIF, recombinant macrophage migration inhibitory factor; and AAR, area at risk.
by DFG grant Ra969/6-1 to Dr Rassaf and Dr Bernhagen, and Ke405/5-1 and FOR 809 to Dr Kelm. Dr Rassaf is a Heisenberg Professor funded by the DFG (Ra969/7-1). Dr Totzek is a scholar of the Deutsche Herzstiftung. Dr Lüdike is a scholar of the German Cardiac Society.
